Intellia Therapeutics, Inc. (NASDAQ:NTLA) is Merlin Capital Inc’s 4th Largest Position

Merlin Capital Inc raised its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 44.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 26,834 shares of the company’s stock after acquiring an additional 8,308 shares during the period. Intellia Therapeutics makes up 2.6% of Merlin Capital Inc’s investment portfolio, making the stock its 4th largest position. Merlin Capital Inc’s holdings in Intellia Therapeutics were worth $818,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Blue Trust Inc. purchased a new position in Intellia Therapeutics during the fourth quarter valued at approximately $26,000. Signaturefd LLC lifted its position in Intellia Therapeutics by 89.3% during the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock valued at $49,000 after purchasing an additional 751 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Intellia Therapeutics by 95.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock valued at $72,000 after purchasing an additional 1,108 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in Intellia Therapeutics by 35.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock valued at $93,000 after purchasing an additional 793 shares during the last quarter. Finally, Pathstone Family Office LLC lifted its holdings in shares of Intellia Therapeutics by 20.3% in the 3rd quarter. Pathstone Family Office LLC now owns 6,438 shares of the company’s stock worth $204,000 after acquiring an additional 1,086 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Trading Down 1.6 %

Shares of NTLA traded down $0.36 during trading hours on Tuesday, reaching $21.62. 366,430 shares of the company traded hands, compared to its average volume of 1,472,580. The company’s fifty day moving average price is $26.39 and its two-hundred day moving average price is $27.47. Intellia Therapeutics, Inc. has a 12 month low of $19.37 and a 12 month high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The business had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. During the same quarter in the previous year, the firm posted ($1.40) earnings per share. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on NTLA shares. Wolfe Research started coverage on shares of Intellia Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $136.00 to $32.00 in a report on Friday, February 23rd. Wedbush reiterated a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. Finally, Canaccord Genuity Group upped their price target on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a report on Friday, February 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $67.00.

Insider Buying and Selling

In related news, EVP James Basta sold 2,297 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now owns 81,571 shares of the company’s stock, valued at $2,691,027.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.00% of the stock is currently owned by insiders.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.